Vacuum-assisted closure device for the management of infected postpneumonectomy chest cavities.

Détails

ID Serval
serval:BIB_CF60E46AF861
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Vacuum-assisted closure device for the management of infected postpneumonectomy chest cavities.
Périodique
Journal of Thoracic and Cardiovascular Surgery
Auteur⸱e⸱s
Perentes J.Y., Abdelnour-Berchtold E., Blatter J., Lovis A., Ris H.B., Krueger T., Gonzalez M.
ISSN
1097-685X (Electronic)
ISSN-L
0022-5223
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
149
Numéro
3
Pages
745-750
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
BACKGROUND: Infected postpneumonectomy chest cavities may be related to chronic postpneumonectomy empyema or arise in rare situations of necrotizing pneumonia with complete lung destruction where pneumonectomy and pleural debridement are required. We evaluated the safety and efficacy of an intrathoracic vacuum-assisted closure device (VAC) for the treatment of infected postpneumonectomy chest cavities.
METHOD: A retrospective single institution review of all patients with infected postpneumonectomy chest cavities treated by VAC between 2005 and 2013. Patients underwent surgical debridement of the thoracic cavity, muscle flap closure of the bronchial stump when a fistula was present, and repeated intrathoracic VAC dressings until granulation tissue covered the entire chest cavity. After this, the cavity was obliterated by a Clagett procedure and closed.
RESULTS: Twenty-one patients (14 men and 7 women) underwent VAC treatment of their infected postpneumonectomy chest cavity. Twelve patients presented with a chronic postpneumonectomy empyema (10 of them with a bronchopleural fistula) and 9 patients with an empyema occurring in the context of necrotizing pneumonia treated by pneumonectomy. In-hospital mortality was 23%. The median duration of VAC therapy was 23 days (range, 4-61 days) and the median number of VAC changes per patient was 6 (range, 2-14 days). Infection control and successful chest cavity closure was achieved in all surviving patients. One adverse VAC treatment-related event was identified (5%).
CONCLUSIONS: The intrathoracic VAC application is a safe and efficient treatment of infected postpneumonectomy chest cavities and allows the preservation of chest wall integrity.
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/04/2015 17:19
Dernière modification de la notice
20/08/2019 15:49
Données d'usage